Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 04, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs. On October 30, 2008, an increase in the notional allocation of Ordinary share ADRs occurred at a price of $37.90 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on October 30, 2008.
- Transaction Price: The price per ADR was $37.90.
- Involved Parties: The notification covers Dr M M Slaoui, Mrs C Bruck Slaoui, Mr E J Gray, Mr W C Louv, and Dr D Pulman.
- Allocation Details: Specific unit increases were 5, 2, 25, 12, and 26 respectively for the individuals listed above.